Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oyster Point Looks To Compete In Dry Eye With Nasal Spray Therapeutic

Executive Summary

Spun out from Oculeve in tandem with that company’s acquisition by Allergan, Oyster Point hopes to develop a nasal spray that can address the underlying cause of dry eye. It has two candidates on parallel courses in Phase II with a goal of choosing one to advance into Phase III.

Advertisement

Related Content

TopiVert Seeks Slot In Dry Eye Disease
Finance Watch: Scripps Research Models A New Way To Fund Translation
Allergan, Shire Battle In Dry Eye As Generics Advance
Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace
US Approvals Analysis: April A Big Month For Non-Invasive Neurostim
Beyond Restasis: Allergan buys Oculeve dry eye device

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel